Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of APG-2575 monotherapy and combination therapy in relapsed or refractory CLL/SLL
CTR20200693Phase 2Active
- Sponsor
- Suzhou Yasheng Pharmaceutical
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lisaftoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Suzhou Yasheng Pharmaceutical. Started Oct 2020; status: active.
02
Drugs
lisaftoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20200693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200693.